BBH

VanEck announced today the following 2025 annual distributions per share for its VanEck® equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 22, 2025 | Record Date: December 22, 2025 | Payable Date: December 26, 2025 Fund Ticker   Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Africa Index ETF AFK $0.2716 5% None None VanEck Biotech ETF BBH $0.9565 None None None VanEck Gaming ETF BJK $1.3636 None None None VanEck Brazil Small-Cap ETF BRF $0.8889 1% None None VanEck Social Sentiment ET

VanEck announced today the following 2024 annual distributions per share for its VanEck® equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 23, 2024 | Record Date: December 23, 2024 | Payable Date: December 24, 2024 Fund Ticker   Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Africa Index ETF AFK None None None None VanEck Biotech ETF BBH $ 1.2517 22% None None VanEck Gaming ETF BJK $ 1.1667 34% None None VanEck Brazil Small-Cap

VanEck announced today the following 2023 annual distributions per share for its VanEck® equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 18, 2023 | Record Date: December 19, 2023 | Payable Date: December 22, 2023 Fund Ticker   Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Africa Index ETF AFK $0.3136 60% None None VanEck Biotech ETF BBH $0.7127 None None None VanEck Gaming ETF BJK $0.7111 6% None None VanEck Brazil

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of the abortion pill mifepristone.  Garland said the administration "will be seeking emergency relief from the Supreme Court to defend the FDA's scientific judgment and protect Americans' access to safe and effective reproductive care." The New Orleans-based 5th U.S. Circuit Court of Appeals put on hold part of last Friday's order by U.S. District Judge Matthew Kacsmaryk in Amarillo, Texas, while he hears a lawsuit by anti-abortion groups seeking to ban it. The Planned Parenthood Federation

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. The abortion pill mifepristone will remain available in the U.S. for now but with some restrictions, including requiring in-person doctor visits to obtain the drug and limiting its use to the first seven weeks of pregnancy from the current ten, a federal appeals court ruled. Related Content: New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications. In his last week ruling, Texas Judge Matthew Kacsmaryk ordered pulling mifepristone from the market in seven days, saying the FDA had vi

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this week. The alternative option, misoprostol, is FDA-approved to treat gastric ulcers, noted CNBC. But the use of misoprostol alone to induce abortions is endorsed by the World Health Organization and is used in countries where mifepristone is unavailable. Also Read: Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead. It will remain on the market if U.S. District Judge Matthew Kacsmaryk's order suspending mifepristone takes effect th

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating risks to millions of people," including those in states where abortion remains legal. The attorneys general, in their filing, called on the U.S. 5th Circuit Court of Appeals to keep mifepristone on the market. Last week Friday, a U.S. judge suspended the FDA's approval of mifepristone, an abortion pill to terminate a pregnancy through ten weeks gestation. But he put his decision on hold for one week to give the Biden administration time to appeal. Also Read - Drugmakers Stand Up for Reproduc

Today, the FDA announced the final decision to withdraw approval of Privately held-Covis Pharma's Makena (hydroxyprogesterone caproate injection), a drug approved under the accelerated approval pathway to reduce the risk of preterm birth.  The decision was issued jointly by the FDA Commissioner and Chief Scientist.  Effective today, Makena and its generics are no longer approved and cannot lawfully be distributed. The FDA approved Makena under the accelerated approval pathway in 2011 based on a determination that the sponsor had demonstrated a drug effect on an intermediate clinical endpoint that was reasonably likely to predict clinical benefit.  The agency's approval required the spo

IBOT offers global exposure to the rise of the robotics industry, which is projected to grow to over $90B by 2026.1 IBOT joins VanEck's forward-looking thematic ETFs lineup, providing a way for investors to invest in the technologies shaping our future. VanEck today announced the launch of the VanEck Robotics ETF (IBOT), a thematic equity ETF offering exposure to the leading global companies that are driving and benefiting from the growth of the robotics industry. As economic environments rapidly shift, labor shortages grow, and the world trends toward deglobalization, the need to introduce more automation and greater efficiency across a range of industries is increasing. "Industrial ro

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is reportedly considering a request by anti-abortion groups to ban sales of the drug nationwide. The judge raised the possibility of keeping the drug on the market but re-imposing some restrictions lifted by Biden's administration, including requiring it to be dispensed in person rather than by mail.  Kacsmaryk said he would rule "as soon as possible." Related: New York Governor, Attorney General Ask Three Pharmacy Operators' Commitment Over Abortion Drug Access. The anti-abortion groups sued th

The FDA issued an "import alert" about the animal tranquilizer xylazine, also called "tranq," "tranq dope," and "zombie drug."  The notice allows agents to seize shipments of xylazine and "unapproved finished drug products" containing it without physically examining the shipments.  The FDA said it will scrutinize incoming xylazine shipments to ensure they are "properly labeled, not adulterated, and for legitimate veterinary use."  Xylazine, a tranquilizer used on large animals, is not approved for human consumption in the U.S., but so far, tranq dope has reportedly spread to at least 39 states, Washington D.C., and Puerto Rico.  Xylazine can depress breathing, blood pressure, heart rat

VanEck announced today the following 2022 annual distributions per share for its VanEck® equity exchange-traded funds. Ex-Date: December 19, 2022 Record Date: December 20, 2022 Payable Date: December 23, 2022 Natural Resources   Ticker Income Approximate % of Income from PFICs Short-Term Capital Gain Long-Term Capital Gain VanEck Agribusiness ETF MOO $ 1.8466 5% None None VanEck Future of Food ETF YUMY $ 0.2560 None None None VanEck Gold Miners ETF GDX $ 0.4762 None None None VanEck Green Metals ETF GMET $ 0.7250 <1% None None VanEck Junior Gold Miners ETF GDXJ $ 0.182

VanEck announced today the following 2021 annual distributions per share for its VanEck® equity exchange-traded funds. Ex-Date: December 20, 2021 Record Date: December 21, 2021 Payable Date: December 27, 2021 Natural Resources ETFs     Ticker     Income     Approximate % of Income from PFICs     Short- Term Capital Gain     Long-Term Capital Gain VanEck Agribusiness ETF     MOO     $1.0968     None     None     None VanEck Future of Food ETF     YUMY     None     None     None     None VanEck Gold Miners ETF     GDX     $0.5348     None     None     None VanEck Green Meta